34 Cathie Wood CRISPR Therapeutics AG Trades
Cathie Wood's position in CRISPR Therapeutics AG is currently worth $644M. That's 4.30% of their equity portfolio (3rd largest holding). The investor owns 11.89% of the outstanding CRISPR Therapeutics AG stock. The first CRISPR Therapeutics AG trade was made in Q2 2017. Since then Cathie Wood bought shares 22 more times and sold shares on thirteen occasions. The investor's estimated purchase price is $746M, resulting in a loss of 14%.
News about CRISPR Therapeutics AG and Cathie Wood
3 Stocks That Cathie Wood Is Loving Now: February 2024
Cathie Wood stocks make headlines for their potential to be at the leading edge of disruptive technologies and generate high returns. Yet, Wood’s flagship AR...
Cathie Wood''s highest conviction stock picks for 2024 include one with ''life-changing innovation''
The innovation investor said her biotech darling CRISPR Therapeutics in the multiomics space has the potential to be her top performer next year.
Cathie Wood Is Buying CRISPR Therapeutics Ahead of This Big Event. Should You?
Wood has outperformed the market so far this year.
The 3 Most Undervalued Cathie Wood Stocks to Buy Now: August 2023
Cathie Wood had a rough few years. Her flagship fund, the ARK Innovation ETF (NYSEARCA: ARKK ), hit an all-time high of $156 in 2021 before crashing back to ...